Cervarix™. Human papillomavirus vaccine

Raphael P. Viscidi; Keerti V. Shah

doi:10.1358/dof.2007.032.11.1150372

Cervarix™. Human papillomavirus vaccine

Raphael P. Viscidi, Keerti V. Shah

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Cervarix™ is a bivalent virus-like particle (VLP) vaccine adjuvanted with monophosphoryl lipid A and alum, designed to provide protection against infection with genital tract human papillomaviruses (HPVs) types 16 and 18, which account for over 70% of cervical cancers. A phase II study and an interim analysis of a phase III study showed that Cervarix™ is safe and well tolerated in young women aged 15-25 years. In both studies, the vaccine was highly immunogenic (100% seroconversion rates) and after 4.5 years of follow-up, vaccine-induced antibody titers were over 14-17-fold higher than those noted for natural infection. The efficacy of Cervarix™ for preventing persistent HPV-16 and/or -18 infection at the cervix was 80-94%. Cervarix™ also provided significant cross-protection against infection with genetically closely related HPV types 31 and 45. Interim analysis of the phase III study indicated that the efficacy of Cervarix™ in preventing HPV-16/18-related cervical intraepithelial neoplasia (CIN) grade 2/3 may be as high as 100%.

Original language	English (US)
Pages (from-to)	952-956
Number of pages	5
Journal	Drugs of the Future
Volume	32
Issue number	11
DOIs	https://doi.org/10.1358/dof.2007.032.11.1150372
State	Published - Nov 2007

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1358/dof.2007.032.11.1150372

Cite this

@article{acae834f0e8b4045aadd810e6c315566,

title = "Cervarix{\texttrademark}. Human papillomavirus vaccine",

abstract = "Cervarix{\texttrademark} is a bivalent virus-like particle (VLP) vaccine adjuvanted with monophosphoryl lipid A and alum, designed to provide protection against infection with genital tract human papillomaviruses (HPVs) types 16 and 18, which account for over 70% of cervical cancers. A phase II study and an interim analysis of a phase III study showed that Cervarix{\texttrademark} is safe and well tolerated in young women aged 15-25 years. In both studies, the vaccine was highly immunogenic (100% seroconversion rates) and after 4.5 years of follow-up, vaccine-induced antibody titers were over 14-17-fold higher than those noted for natural infection. The efficacy of Cervarix{\texttrademark} for preventing persistent HPV-16 and/or -18 infection at the cervix was 80-94%. Cervarix{\texttrademark} also provided significant cross-protection against infection with genetically closely related HPV types 31 and 45. Interim analysis of the phase III study indicated that the efficacy of Cervarix{\texttrademark} in preventing HPV-16/18-related cervical intraepithelial neoplasia (CIN) grade 2/3 may be as high as 100%.",

author = "Viscidi, {Raphael P.} and Shah, {Keerti V.}",

year = "2007",

month = nov,

doi = "10.1358/dof.2007.032.11.1150372",

language = "English (US)",

volume = "32",

pages = "952--956",

journal = "Drugs of the Future",

issn = "0377-8282",

publisher = "Prous Science",

number = "11",

}

TY - JOUR

T1 - Cervarix™. Human papillomavirus vaccine

AU - Viscidi, Raphael P.

AU - Shah, Keerti V.

PY - 2007/11

Y1 - 2007/11

N2 - Cervarix™ is a bivalent virus-like particle (VLP) vaccine adjuvanted with monophosphoryl lipid A and alum, designed to provide protection against infection with genital tract human papillomaviruses (HPVs) types 16 and 18, which account for over 70% of cervical cancers. A phase II study and an interim analysis of a phase III study showed that Cervarix™ is safe and well tolerated in young women aged 15-25 years. In both studies, the vaccine was highly immunogenic (100% seroconversion rates) and after 4.5 years of follow-up, vaccine-induced antibody titers were over 14-17-fold higher than those noted for natural infection. The efficacy of Cervarix™ for preventing persistent HPV-16 and/or -18 infection at the cervix was 80-94%. Cervarix™ also provided significant cross-protection against infection with genetically closely related HPV types 31 and 45. Interim analysis of the phase III study indicated that the efficacy of Cervarix™ in preventing HPV-16/18-related cervical intraepithelial neoplasia (CIN) grade 2/3 may be as high as 100%.

AB - Cervarix™ is a bivalent virus-like particle (VLP) vaccine adjuvanted with monophosphoryl lipid A and alum, designed to provide protection against infection with genital tract human papillomaviruses (HPVs) types 16 and 18, which account for over 70% of cervical cancers. A phase II study and an interim analysis of a phase III study showed that Cervarix™ is safe and well tolerated in young women aged 15-25 years. In both studies, the vaccine was highly immunogenic (100% seroconversion rates) and after 4.5 years of follow-up, vaccine-induced antibody titers were over 14-17-fold higher than those noted for natural infection. The efficacy of Cervarix™ for preventing persistent HPV-16 and/or -18 infection at the cervix was 80-94%. Cervarix™ also provided significant cross-protection against infection with genetically closely related HPV types 31 and 45. Interim analysis of the phase III study indicated that the efficacy of Cervarix™ in preventing HPV-16/18-related cervical intraepithelial neoplasia (CIN) grade 2/3 may be as high as 100%.

UR - http://www.scopus.com/inward/record.url?scp=38649085635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649085635&partnerID=8YFLogxK

U2 - 10.1358/dof.2007.032.11.1150372

DO - 10.1358/dof.2007.032.11.1150372

M3 - Article

AN - SCOPUS:38649085635

SN - 0377-8282

VL - 32

SP - 952

EP - 956

JO - Drugs of the Future

JF - Drugs of the Future

IS - 11

ER -

Cervarix™. Human papillomavirus vaccine

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this